14 October 2026 Formats | PDF | Category: Pharma and Healthcare | Delivery: 24 to 72 Hours
Open-Angle Glaucoma (OAG) Market Size Statistics
Market Size (2026): USD 6.9 Billion
Forecast (2034): USD 10.5 Billion
CAGR (2026–2034): 5.5%
Base Year: 2025 (USD 6.5 Billion)
Leading Segment (2026): Prostaglandin analogs (drug class)
Leading Region (2026): North America (~38–40% share)
Core Trends: Sustained-release, procedure-based drug delivery implants are starting to replace daily eye drops in open-angle glaucoma, targeting poor adherence to topical therapy.
Open-Angle Glaucoma (OAG) Market Definition
The OAG market consists of prescription drugs that help reduce intraocular pressure (IOP) and inhibit optic nerve damage in patients suffering from open-angle glaucoma and ocular hypertension when it is being managed under open-angle glaucoma. The products include both topical eye drops as well as extended-release drug delivery systems. It does not include any of the angle-closure glaucoma treatments.
Open-Angle Glaucoma (OAG) Market Overview 2026
The 2026 Open-Angle Glaucoma (OAG) Market will be propelled by the increasing demand for early diagnosis, disease management, pressure-lowering drugs, lasers and glaucoma surgeries. OAG is a type of an eye disease which destroys the optic nerve, thus causing permanent blindness. Due to the fact that the disease progresses gradually, it may remain unnoticed; hence the necessity for timely examination and treatment. The population aging, increasing consciousness about eye health as well as the necessity for lifelong management are among the factors driving demand for diagnostics and treatment.
Increasing demand for prescription eye drops, innovations in ophthalmic diagnostics, use of laser-based treatments and advancements in glaucoma surgeries are among the major trends which influence the growth of the market. Medications such as prostaglandin analogs and intraocular-pressure lowering drugs continue to play a significant role in OAG treatment. However, selective laser trabeculoplasty and minimally-invasive glaucoma surgeries are also developing as treatment approaches.
The Open-Angle Glaucoma Market is characterized by trends that include the introduction of treatment techniques that enhance pressure control and adherence among patients. The improvements in imaging tools such as optical coherence tomography and visual field assessment are aiding healthcare specialists in evaluating the optic nerve damage and the progress of the disease. In addition, there is an improvement in pharmaceutical companies’ efforts in improving and inventing new medications for the disease whereas there is improvement in the devices used by healthcare practitioners including laser equipment and surgeries in glaucoma treatments.
North America continues to be an important market owing to the presence of eye care institutions, prescription medications, and surgical services available in the region. Europe will benefit from eye care facilities as well as ageing population. On the other hand, Asia Pacific will gain from its huge population and increasing need for eye examinations.
Request a Free Sample Copy: https://forinsightsconsultancy.com/reports/request-sample-open-angle-glaucoma-oag-market (Sample Include key points such as 2026 market size, 2034 forecast, CAGR, leading product segment, fastest-growing segment, dominant region, major companies, trends, growth drivers, challenges, and opportunities.)
Trends 2026
Sustained-release delivery (the core trend)
Adherence forms the core of this argument. According to a study quoted by Ophthalmology Management, just 10% of patients were consistent in taking their eye drops over the course of a year. The implants like Durysta, which received FDA approval in 2020, and iDose TR, which was approved in 2023, aim to relieve this hassle. In January 2026, the FDA approved the repeated administration of iDose TR for the treatment of open-angle glaucoma and ocular hypertension. Glaukos reported sales of USD 136 million for iDose TR in 2025.
A broader sustained-delivery pipeline
The Review of Ophthalmology highlights how Glaukos has launched a Phase IIb/III clinical trial for iDose TREX, a formulation capable of holding twice the amount of drug. OTX-TIC, an intracameral hydrogel implant for delivering travoprost, and a drug-eluting intraocular lens platform by Spyglass Pharma are other notable drug delivery systems. Cataract surgeries present an ideal target for such systems.
A more procedural treatment paradigm
Management of Ophthalmology states that the paradigm shift in glaucoma is taking place from a treatment-oriented intervention to an intervention with a combination of drugs with different mechanism, drug delivery device, minimally invasive glaucoma surgery, and laser trabeculoplasty. That is the reason that companies focusing on devices and procedures are entering this field, like Bausch + Lomb, which acquired Elios Vision in December 2024.
New drug classes and geographic expansion
Growth drivers identified by DelveInsight include introduction of novel drugs and launches of these drugs. Existing drugs are also being introduced in new geographies. In April 2025, Santen got approval from the Chinese regulatory body for tafluprost/timolol maleate for open-angle glaucoma and ocular hypertension.
Open-Angle Glaucoma (OAG) Market Growth Drivers 2026
Population aging and rising prevalence (primary driver)
Growth is attributed to the increase in the global prevalence of glaucoma along with the increase in the geriatric population prone to eye diseases related to age. According to Ken Research, there are about 80 million people suffering from glaucoma which will be around 112 million in 2040 according to the Glaucoma Research Foundation. DelveInsight’s first growth driver is the aging population and increased prevalence of open-angle glaucoma.
A silent disease, brought into treatment through awareness and screening
IMARC notes that open angle glaucoma is the most common form owing to the fact that it is prevalent, progressive and largely asymptomatic in nature. According to the market reports, there are other reasons too such as increasing awareness about the need for early detection and treatment of the disease.
Risk factors in the wider population
Prevalence is affected by advanced age, family history, diabetes, hypertension, and trauma to the eyes. As more people suffer from chronic illnesses, the risk pool expands.
New drug classes and an active pipeline
The DelveInsight factors include novel classes of drugs for open-angle glaucoma and their launches. For Technavio, one of the key reasons for growth is the development of biologics for the treatment of glaucoma in the coming years.
Top Companies Covered in the Open-Angle Glaucoma (OAG) Market are
- AbbVie Inc.
- Santen Pharmaceutical Co., Ltd.
- Alcon Inc.
- Novartis AG
- Pfizer Inc.
Open-Angle Glaucoma (OAG) Market Company news 2026
Santen and AbbVie
Santen announced on April 17 that its China subsidiary had entered into a distribution and promotion agreement with AbbVie for five marketed glaucoma eye drops in the Chinese market.
Glaukos
The FDA approved a labeling supplement allowing unlimited re-administration of iDose TR in patients who maintain a healthy cornea.
Open-Angle Glaucoma (OAG) Market Segments
By Drug Class
- Prostaglandin analogs: First-line drops that increase fluid drainage from the eye. They are the leading class, dominating pharmacotherapy thanks to once-daily dosing and favorable side-effect profiles.
- Beta blockers: Drops that reduce fluid production in the eye. They are an established option, often used when a prostaglandin is unsuitable or as an add-on.
By Disease Type
- Primary open-angle glaucoma (POAG): The most common form, with no identifiable cause other than gradual drainage resistance. It makes up the bulk of the market.
- Secondary open-angle glaucoma: Open-angle disease caused by another condition, injury or medication, a smaller segment.
By Delivery Type
- Topical eye drops: The standard of care, taken daily at home, and nearly all of the market by value.
- Sustained-release implants: Procedure-placed drug implants that release medicine over months, an emerging segment aimed at poor adherence to drops.
By Distribution Channel
- Hospital pharmacy: Supplies treatment for patients managed in hospitals and specialist eye clinics, including newer procedural products.
- Retail pharmacy: The main channel for repeat prescriptions of eye drops.
Open-Angle Glaucoma (OAG) Market Regional Insights 2026
North America:
The largest market belongs to North America. As per Straits Research, it owes its dominance to infrastructural facilities and is projected to grow by 5.32% during the forecast period. This is also the region where latest delivery products are introduced.
Europe:
Europe is the second-biggest region and has low growth. The reasons include old age population, good health care standards, and increased consciousness about early diagnoses and treatment.
Asia-Pacific:
The growth region is the Asia-Pacific region. According to Fortune Business Insights, it is due to the increasing geriatric population in countries such as China and Japan. According to Mordor Intelligence, China is working to liberalize its drug approval process, while India is expanding AI-driven screening facilities.
Latin America & Middle East & Africa
Latin America and Middle East and Africa are small and uneven, and growth depends on access to treatment. I put these two together because the sources divide them inconsistently.
Frequently Asked Questions
How big is the open-angle glaucoma market in 2026?
The market value is forecasted to reach US$ 6.9 billion by 2026, from the base year valuation of US$ 6.5 billion in 2025.
What is the OAG market forecast for 2034, and what is the CAGR?
We forecast around USD 10.5 billion by 2034 at a CAGR of 5.5% during 2026-2034. The published CAGR values are between 2.86% for glaucoma therapies and 6.9% for open-angle glaucoma therapies.
What are the main segments of the OAG market?
By Drug Class (Prostaglandin Analogues, Beta Blockers, Alpha Agonists, Carbonic Anhydrase Inhibitors, Combinations and Others); By Disease (Primary Open Angle and Secondary Open Angle); By Method (Eye Drops and Sustained Release Implants) and By Channel (Hospital, Retail and Online Pharmacy).
What’s Included in This Report — Open-Angle Glaucoma (OAG) Market
This report provides a comprehensive analysis of the Open-Angle Glaucoma (OAG) Market, covering the following:
- Market definition and scope: What counts as the open-angle glaucoma market (prescription therapeutics, including drops and sustained-release implants), what is excluded (angle-closure glaucoma, surgery, devices and diagnostics), and why published figures differ.
- Market size and forecast: 2025 base year (USD 6.5 billion), 2026 size (USD 6.9 billion) and the 2034 forecast (USD 10.5 billion) at a 5.5% CAGR.
- Competitor benchmarking: A comparison of third-party research estimates, scaled from glaucoma-wide reports to open-angle disease, showing how the independent values were derived.
- Segmentation analysis: Breakdown by drug class, disease type, delivery type and distribution channel, with the leading segment (prostaglandin analogs) identified.
- Regional insights: Shares, 2026 and 2034 sizes and growth rates for North America, Europe, Asia-Pacific, and Latin America with Middle East & Africa.
- Growth drivers, restraints and trends: What is pushing demand (population aging, rising diagnosis, adherence-focused innovation) and what could slow it (generic pricing pressure, reimbursement uncertainty, high treatment cost), plus the core 2026 trend.
- Competitive landscape: The companies named in the market, including AbbVie, Alcon, Santen, Bausch + Lomb, Novartis, Pfizer and Glaukos, with recent company developments.
Why Buy This Research Report?
- Independent, scope-adjusted numbers: Most publishers size the whole glaucoma market, and the few open-angle figures range from about USD 5.4 billion to over USD 9 billion for the same period. We compare them, adjust for scope and give one defensible estimate: USD 6.9 billion in 2026, growing to USD 10.5 billion by 2034.
- Transparent methodology: You see how each value was derived, including how glaucoma-wide reports were scaled to open-angle disease, which sources were included or excluded, and why.
- Clear market definition: The report separates open-angle therapeutics from angle-closure disease, surgery, devices and diagnostics, so the numbers match what drug and delivery companies actually sell.
- Tied to real demand drivers: Growth is linked to population aging, rising diagnosis, adherence problems with daily drops and the move toward sustained-release delivery.
- Regional and segment clarity: See where demand is concentrated (North America), where it is growing fastest (Asia-Pacific), and which drug class leads (prostaglandin analogs).
- Competitive context: Shows who the key companies are and what they did in 2026, from product launches and pipeline setbacks to distribution deals.
Buy This Report Now — https://forinsightsconsultancy.com/buy-now-open-angle-glaucoma-oag-market (Access In-Depth Analysis, Forecasts & Company Profiles)
Related Market Reports of Pharma and Healthcare Industry
Wet Age Related Macular Degeneration (AMD) Market Size
Beta Blockers Market Size, Share
Table of Contents
- Executive Summary
- Open-Angle Glaucoma (OAG) Industry Characteristics
- Open-Angle Glaucoma (OAG) Industry Trends And Strategies
- Open-Angle Glaucoma (OAG) Industry – Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
- Global Open-Angle Glaucoma (OAG) Growth Analysis And Strategic Analysis Framework
5.1. Global Open-Angle Glaucoma (OAG) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Open-Angle Glaucoma (OAG) Industry Growth Rate Analysis
5.4. Global Open-Angle Glaucoma (OAG) Historic Market Size and Growth, 2019 – 2024, Value ($ Billion)
5.5. Global Open-Angle Glaucoma (OAG) Forecast Market Size and Growth, 2025- 2034, 2034F, Value ($ Billion)
5.6. Global Open-Angle Glaucoma (OAG) Total Addressable Market (TAM)
- Open-Angle Glaucoma (OAG) Industry Segmentation
6.1. Global Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
Open Angle Glaucoma
Angle Closure Glaucoma
Other Disease Type
6.2. Global Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
Prostaglandin Analog
Beta Blockers
Adrenergic Agonist
Carbonic Anhydrase Inhibitors
Others Drug Class
6.3. Global Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End Users
6.4. Global Open-Angle Glaucoma (OAG) Industry, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
6.5. Global Open-Angle Glaucoma (OAG) Industry, Sub-Segmentation Of Open Angle Glaucoma, By Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
Primary Open-Angle Glaucoma (POAG)
Secondary Open-Angle Glaucoma
6.6. Global Open-Angle Glaucoma (OAG) Industry, Sub-Segmentation Of Angle Closure Glaucoma, By Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
Acute Angle-Closure Glaucoma
Chronic Angle-Closure Glaucoma
6.7. Global Open-Angle Glaucoma (OAG) Industry, Sub-Segmentation Of Other Disease Type, By Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
Normal-Tension Glaucoma
Congenital Glaucoma
Secondary Glaucoma
- Open-Angle Glaucoma (OAG) Industry Regional And Country Analysis
7.1. Global Open-Angle Glaucoma (OAG) Industry, Split By Region, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
7.2. Global Open-Angle Glaucoma (OAG) Industry, Split By Country, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- Asia-Pacific Open-Angle Glaucoma (OAG) Industry
8.1. Asia-Pacific Open-Angle Glaucoma (OAG) Industry Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
8.3. Asia-Pacific Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
8.4. Asia-Pacific Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- China Open-Angle Glaucoma (OAG) Industry
9.1. China Open-Angle Glaucoma (OAG) Industry Overview
9.2. China Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F,$ Billion
9.3. China Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F,$ Billion
9.4. China Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F,$ Billion
- India Open-Angle Glaucoma (OAG) Industry
10.1. India Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
10.2. India Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
10.3. India Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- Japan Open-Angle Glaucoma (OAG) Industry
11.1. Japan Open-Angle Glaucoma (OAG) Industry Overview
11.2. Japan Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
11.3. Japan Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
11.4. Japan Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- Australia Open-Angle Glaucoma (OAG) Industry
12.1. Australia Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
12.2. Australia Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
12.3. Australia Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- Indonesia Open-Angle Glaucoma (OAG) Industry
13.1. Indonesia Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
13.2. Indonesia Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
13.3. Indonesia Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- South Korea Open-Angle Glaucoma (OAG) Industry
14.1. South Korea Open-Angle Glaucoma (OAG) Industry Overview
14.2. South Korea Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
14.3. South Korea Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
14.4. South Korea Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- Western Europe Open-Angle Glaucoma (OAG) Industry
15.1. Western Europe Open-Angle Glaucoma (OAG) Industry Overview
15.2. Western Europe Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
15.3. Western Europe Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
15.4. Western Europe Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- UK Open-Angle Glaucoma (OAG) Industry
16.1. UK Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
16.2. UK Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
16.3. UK Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- Germany Open-Angle Glaucoma (OAG) Industry
17.1. Germany Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
17.2. Germany Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
17.3. Germany Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- France Open-Angle Glaucoma (OAG) Industry
18.1. France Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
18.2. France Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
18.3. France Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- Italy Open-Angle Glaucoma (OAG) Industry
19.1. Italy Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
19.2. Italy Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
19.3. Italy Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- Spain Open-Angle Glaucoma (OAG) Industry
20.1. Spain Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
20.2. Spain Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
20.3. Spain Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- Eastern Europe Open-Angle Glaucoma (OAG) Industry
21.1. Eastern Europe Open-Angle Glaucoma (OAG) Industry Overview
21.2. Eastern Europe Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
21.3. Eastern Europe Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
21.4. Eastern Europe Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- Russia Open-Angle Glaucoma (OAG) Industry
22.1. Russia Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
22.2. Russia Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
22.3. Russia Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- North America Open-Angle Glaucoma (OAG) Industry
23.1. North America Open-Angle Glaucoma (OAG) Industry Overview
23.2. North America Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
23.3. North America Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
23.4. North America Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- USA Open-Angle Glaucoma (OAG) Industry
24.1. USA Open-Angle Glaucoma (OAG) Industry Overview
24.2. USA Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
24.3. USA Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
24.4. USA Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- Canada Open-Angle Glaucoma (OAG) Industry
25.1. Canada Open-Angle Glaucoma (OAG) Industry Overview
25.2. Canada Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
25.3. Canada Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
25.4. Canada Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- South America Open-Angle Glaucoma (OAG) Industry
26.1. South America Open-Angle Glaucoma (OAG) Industry Overview
26.2. South America Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
26.3. South America Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
26.4. South America Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- Brazil Open-Angle Glaucoma (OAG) Industry
27.1. Brazil Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
27.2. Brazil Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
27.3. Brazil Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- Middle East Open-Angle Glaucoma (OAG) Industry
28.1. Middle East Open-Angle Glaucoma (OAG) Industry Overview
28.2. Middle East Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
28.3. Middle East Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
28.4. Middle East Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- Africa Open-Angle Glaucoma (OAG) Industry
29.1. Africa Open-Angle Glaucoma (OAG) Industry Overview
29.2. Africa Open-Angle Glaucoma (OAG) Industry, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
29.3. Africa Open-Angle Glaucoma (OAG) Industry, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
29.4. Africa Open-Angle Glaucoma (OAG) Industry, Segmentation By End User, Historic and Forecast, 2019-2024, 2025-2034F, 2034F, $ Billion
- Open-Angle Glaucoma (OAG) Industry Competitive Landscape And Company Profiles
30.1. Open-Angle Glaucoma (OAG) Industry Competitive Landscape
30.2. Open-Angle Glaucoma (OAG) Industry Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
- Open-Angle Glaucoma (OAG) Industry Other Major And Innovative Companies
31.1. Teva Pharmaceutical Industries Ltd.
31.2. Boston Scientific
31.3. Alcon Inc.
31.4. Bausch Health Companies Inc.
31.5. Hoya Corporation
31.6. Sun Pharmaceutical Industries Ltd.
31.7. Santen Pharmaceuticals
31.8. Mallinckrodt Pharmaceuticals
31.9. Théa Pharma
31.10. Glaukos Corporation
31.11. Quantel Medical
31.12. EyePoint Pharmaceuticals Inc.
31.13. iSTAR Medical
31.14. Nicox Ophthalmics
31.15. Visus Therapeutics
- Global Open-Angle Glaucoma (OAG) Industry Competitive Benchmarking And Dashboard
- Key Mergers And Acquisitions In The Open-Angle Glaucoma (OAG) Industry
- Recent Developments In The Open-Angle Glaucoma (OAG) Industry
- Open-Angle Glaucoma (OAG) Industry High Potential Countries, Segments and Strategies
35.1 Open-Angle Glaucoma (OAG) Industry In 2034 – Countries Offering Most New Opportunities
35.2 Open-Angle Glaucoma (OAG) Industry In 2034 – Segments Offering Most New Opportunities
35.3 Open-Angle Glaucoma (OAG) Industry In 2034 – Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
- Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. For Insights Consultancy
36.6. Copyright And Disclaimer
Select PDF License
Single User: $1999
Multiple Users: $3999
Corporate Users: $4999
